Computational Biology and Drug Discovery: From Single-Target to Network Drugs
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The drug discovery process is complex, time consuming and expensive, and includes preclinical and clinical phases. The pharmaceutical industry is moving from a symptomatic relief focus towards a more pathology-based approach where a better understanding of the pathophysiology should help deliver drugs whose targets are involved in the causative processes underlying the disease. Computational biology and bioinformatics have the potential not only to speed up the drug discovery process, thus reducing the costs, but also to change the way drugs are designed. In this review we focus on the different computational and bioinformatics approaches that have been proposed and applied to the different steps involved in the drug development process. The development of network-reconstruction methods is now making it possible to infer a detailed map of the regulatory circuit among genes, proteins and metabolites. It is likely that the development of these technologies will radically change, in the next decades, the drug discovery process, as we know it today. Keywords: lead identification, Supervised-learning methods, Leukemia, titration-invariant similarity score (TISS), bioinformatics, reverse engineering
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are theoretical grounds, as well as abundant evidence, to the effect that several steps in a network must be modulated simultaneously to exhibit substantial effects”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Ambesi-Impiombato and di Bernardo 2006
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
(1975) · CERN Document Server (European Organization for Nuclear Research) · Cited by 5,958
Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes
Gasch, A. P., Spellman, P. T., Kao, C. M., Carmel-Harel, O., Eisen, M. B., Storz, G., Botstein, D., & Brown, P. O. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4241 · Cited by 4,815 · cited 2×
“[11] that performed a hierarchical clustering of 142 whole-genome arrays in S.”
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Knowledge-based analysis of microarray gene expression data by using support vector machines
Brown, M. P. S., Grundy, W. N., Lin, D., Cristianini, N., Sugnet, C. W., Furey, T. S., Ares, M., & Haussler, D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.262 · Cited by 2,308
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Reverse engineering of regulatory networks in human B cells
Basso, K., Margolin, A. A., Stolovitzky, G., Klein, U., Dalla-Favera, R., & Califano, A. (2005) · Nature Genetics · doi:10.1038/ng1532 · Cited by 1,404
Inferring Genetic Networks and Identifying Compound Mode of Action via Expression Profiling
Gardner, T. S., di Bernardo, D., Lorenz, D., & Collins, J. J. (2003) · Science · doi:10.1126/science.1081900 · Cited by 1,117
Self-citationHughes, J. D., Estep, P. W., Tavazoie, S., & Church, G. M. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3519 · Cited by 1,010
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · cited 2×
“[46] in their review, where they propose the partial inactivation of multiple targets as a novel paradigm for drug design.”
BackgroundChemosensitivity prediction by transcriptional profiling
Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191368598 · Cited by 684
Parsons, A. B., Brost, R. L., Ding, H., Li, Z., Zhang, C., Sheikh, B., Brown, G. W., Kane, P. M., Hughes, T. R., & Boone, C. (2004) · Nature Biotechnology · doi:10.1038/nbt919 · Cited by 675
Multidimensional Drug Profiling By Automated Microscopy
Perlman, Z. E., Slack, M. D., Feng, Y., Mitchison, T. J., Wu, L. F., & Altschuler, S. J. (2004) · Science · doi:10.1126/science.1100709 · Cited by 660
Drug target validation and identification of secondary drug target effects using DNA microarrays
Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., et al. (1998) · Nature Medicine · doi:10.1038/3282 · Cited by 643
Systems biology in drug discovery
Butcher, E. C., Berg, E. L., & Kunkel, E. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1017 · Cited by 605
Exploration of Essential Gene Functions via Titratable Promoter Alleles
Mnaimneh, S., Davierwala, A. P., Haynes, J., Moffat, J., Peng, W.-T., Zhang, W., Yang, X., Pootoolal, J., Chua, G., Lopez, A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.013 · Cited by 604 · cited 1×
“cerevisiae using as a training data set 515 wholegenome yeast expression profiles resulting from a variety of treatment [9,43].”
MethodGenomic profiling of drug sensitivities via induced haploinsufficiency
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., & Davis, R. W. (1999) · Nature Genetics · doi:10.1038/6791 · Cited by 570
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast
Giaever, G., Flaherty, P., Kumm, J., Proctor, M., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., & Davis, R. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307490100 · Cited by 504
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 481
Gene Expression Analysis Reveals Chemical-Specific Profiles
Hamadeh, H. K. (2002) · Toxicological Sciences · doi:10.1093/toxsci/67.2.219 · Cited by 426
Qualitative simulation of genetic regulatory networks using piecewise-linear models
DEJONG, H., GOUZE, J., HERNANDEZ, C., PAGE, M., SARI, T., & GEISELMANN, J. (2004) · Bulletin of Mathematical Biology · doi:10.1016/j.bulm.2003.08.010 · Cited by 386
Cosma, M. P., Pepe, S., Annunziata, I., Newbold, R. F., Grompe, M., Parenti, G., & Ballabio, A. (2003) · Cell · doi:10.1016/s0092-8674(03)00348-9 · Cited by 365
Chemogenomics: an emerging strategy for rapid target and drug discovery
Bredel, M., & Jacoby, E. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1317 · Cited by 356
Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks
di Bernardo, D., Thompson, M. J., Gardner, T. S., Chobot, S. E., Eastwood, E. L., Wojtovich, A. P., Elliott, S. J., Schaus, S. E., & Collins, J. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1075 · Cited by 344
Self-citationDan, S., Tsunoda, T., Kitahara, O., Yanagawa, R., Zembutsu, H., Katagiri, T., Yamazaki, K., Nakamura, Y., & Yamori, T. (2002) · PubMed · Cited by 282
Prediction of Compound Signature Using High Density Gene Expression Profiling
Hamadeh, H. K. (2002) · Toxicological Sciences · doi:10.1093/toxsci/67.2.232 · Cited by 270
Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation
Stegmaier, K., Ross, K. N., Colavito, S. A., O'Malley, S., Stockwell, B. R., & Golub, T. R. (2004) · Nature Genetics · doi:10.1038/ng1305 · Cited by 268
Reverse-engineering transcription control networks
GARDNER, T., & FAITH, J. (2005) · Physics of Life Reviews · doi:10.1016/j.plrev.2005.01.001 · Cited by 234
Li, L., Darden, T., Weingberg, C., Levine, A., & Pedersen, L. (2001) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207013330733 · Cited by 196
Early prediction of drug metabolism and toxicity: systems biology approach and modeling
Bugrim, A., Nikolskaya, T., & Nikolsky, Y. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02971-4 · Cited by 188
Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action
Baetz, K., McHardy, L., Gable, K., Tarling, T., Rebérioux, D., Bryan, J., Andersen, R. J., Dunn, T., Hieter, P., & Roberge, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307122101 · Cited by 177
DEVELOPMENT OF A SYSTEM FOR THE INFERENCE OF LARGE SCALE GENETIC NETWORKS
Maki, Y., Tominaga, D., Okamoto, M., WATANABE, S., & Eguchi, Y. (2000) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814447362_0044 · Cited by 159
Finding the target after screening the phenotype
Hart, C. P. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03415-x · Cited by 148
Betts, J. C., McLaren, A., Lennon, M. G., Kelly, F. M., Lukey, P. T., Blakemore, S. J., & Duncan, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2903-2913.2003 · Cited by 144
How molecular profiling could revolutionize drug discovery
Stoughton, R. B., & Friend, S. H. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1696 · Cited by 118
A partnership between biology and engineering
Brent, R. (2004) · Nature Biotechnology · doi:10.1038/nbt1004-1211 · Cited by 113
Illuminating drug discovery with biological pathways
Apic, G., Ignjatovic, T., Boyer, S., & Russell, R. B. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.02.023 · Cited by 112
Yeast genomics and proteomics in drug discovery and target validation.
Parsons, A. B., Geyer, R., Hughes, T. R., & Boone, C. M. (2003) · PubMed · Cited by 63
Haggarty, S. J., Clemons, P. A., & Schreiber, S. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja035413p · Cited by 61 · cited 1×
“Haggarty 2003 [41] Hit identification, Lead identification”
Effect of catalase-specific inhibitor 3-amino-1,2,4-triazole on yeast peroxisomal catalase in vivo
Ueda, M., Kinoshita, H., Yoshida, T., Kamasawa, N., Osumi, M., & Tanaka, A. (2003) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(02)01201-6 · Cited by 48
The continuing evolution of the drug discovery process in the pharmaceutical industry
Ratti, E., & Trist, D. G. (2001) · Il Farmaco · doi:10.1016/s0014-827x(01)01019-9 · Cited by 35
Pharmaceutical Target Identification by Gene Expression Analysis
Walker, M. (2001) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557013407034 · Cited by 32
Use of Gene Networks for Identifying and Validating Drug Targets
Imoto, S., Savoie, C. J., Aburatani, S., Kim, S., Tashiro, K., Kuhara, S., & Miyano, S. (2003) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720003000290 · Cited by 30
Gunther, E. C., Stone, D. J., Rothberg, J. M., & Gerwien, R. W. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500300 · Cited by 19
Bioinformatics, target discovery and the pharmaceutical/biotechnology industry.
Fagan, R., & Swindells, M. B. (2000) · PubMed · Cited by 13
Bao, L., Guo, T., & Sun, Z. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02515-2 · Cited by 10
Cited by
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
How to infer gene networks from expression profiles
Bansal, M., Belcastro, V., Ambesi‐Impiombato, A., & di Bernardo, D. (2007) · Molecular Systems Biology · doi:10.1038/msb4100120 · Cited by 766
Self-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Identifying Network of Drug Mode of Action by Gene Expression Profiling
Iorio, F., Tagliaferri, R., & Bernardo, D. D. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.10tt · Cited by 101
Self-citation
Metadata
- Authors
- Ambesi-Impiombato, A., & Bernardo, D.
- Affiliations
- Telethon Institute Of Genetics And Medicine (IT)
- Corresponding author
- Bernardo, Diego
- ORCID
- Bernardo, Diego
- Venue
- Current Bioinformatics
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-01-01
- Volume
- 1
- Issue
- 1
- Pages
- 3-13
- ISSN
- 1574-8936 (ISSN-L)
- OpenAlex
- W2003081615
- Cited by
- 47
- References
- 49
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 2 · 2014: 1 · 2013: 2 · 2012: 5
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Bioinformatics (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Keywords
- computational drug discovery, network inference, gene regulatory networks, protein-protein interaction network, metabolite networks, lead compound identification, supervised learning, leukemia, reverse engineering, drug target identification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.